StockMacro
Company, fund or insider

Help

Menu

Neuphoria Therapeutics

$2.35 -57% in 6 monthsMarket cap $12.7M

NEUP on XNAS, Health Care, Neuphoria Therapeutics Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 44% in 12 months, but cash of $18.7M exceeds the $12.6M market cap.

  • BadInstitutional holders fell to 18 from 22 in the latest quarter
  • WatchNews: 8 articles in 7 days, 8 times its usual week

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.

Industry
Pharmaceutical preparations (Health Care)
Employees
1
Website
neuphoriatx.com
Listed
Nasdaq, US
Last results
20 May 2025
Next results
no estimate
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $1.4M.
Quarter to 30 Sep 2023: revenue –, net income -$5.5MQuarter to 31 Dec 2023: revenue –, net income -$4.6MQuarter to 31 Mar 2024: revenue –, net income -$2.8MQuarter to 30 Jun 2024: revenue –, net income -$2.7MQuarter to 30 Sep 2024: revenue –, net income -$805KQuarter to 31 Dec 2024: revenue $663K, net income -$1.9MQuarter to 31 Dec 2024: revenue $663K, net income -$1.9MQuarter to 31 Mar 2025: revenue $15.0M, net income $11.3MQuarter to 31 Mar 2025: revenue $15.0M, net income $11.3MQuarter to 30 Jun 2025: revenue –, net income -$8.9MQuarter to 30 Sep 2025: revenue –, net income -$9.9MQuarter to 31 Dec 2025: revenue –, net income $1.9MQuarter to 31 Mar 2026: revenue –, net income -$505KQuarter to 30 Jun 2026: revenue –, net income -$4.9MQuarter to 30 Sep 2026: revenue –, net income -$1.4M
30 Sep 2023RevenueNet incomeNet losstallest bar $15.0M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$1.4M
30 Jun 2026–-$4.9M
31 Mar 2026–-$505K
31 Dec 2025–$1.9M
30 Sep 2025–-$9.9M
30 Jun 2025–-$8.9M
31 Mar 2025$15.0M$11.3M
31 Dec 2024$663K-$1.9M
30 Sep 2024–-$805K
30 Jun 2024–-$2.7M
31 Mar 2024–-$2.8M
31 Dec 2023–-$4.6M
30 Sep 2023–-$5.5M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$5.0M -$9.5M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -27.6% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $18.7M $13.6M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$18.7M (net cash) -$13.6M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $4.34
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.54 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Neuphoria TherapeuticsNEUP (this company) $12.7Mloss–––
Seres TherapeuticsMCRB $12.6Mloss5.9+505%–
Bolt BiotherapeuticsBOLT $12.8Mloss5.1-51%–
Allarity TherapeuticsALLR $12.6Mloss35.9––
Tvardi TherapeuticsTVRD $13.2Mloss–––
MIRA PharmaceuticalsMIRA $12.2Mloss–––

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-18%

18 13F filers vs 22

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

33%

1.8M shares held by 13F filers (30 Sep 2026) of 5.4M outstanding (13 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

0.2%

12K shares sold short (30 Oct 2026) of 5.4M outstanding (13 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.0

12K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+93%

6,429 shares sold short in the report before, 12K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

54%

54% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 36%

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

8

8 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

8.0×

8 articles in the last 7 days; its usual week has 1.

Price $2.35 on 20 Nov 2026, -44% over 12 months (12-month range $2.27 to $5.48)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $3.3M).
Revenue per quarter. Revenue $15.0M in the latest quarter.
Institutional holders (13F filers). 18 13F filers reported holding it in the latest 13F quarter, +20% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, capital spending per quarter, federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
7 Jan 20268-K and other filingsA major agreement ended
18 Dec 20258-K and other filingsDelisting notice or listing transfer
16 Sep 20258-K and other filingsDelisting notice or listing transfer
18 Jul 20258-K and other filingsDelisting notice or listing transfer
15 May 20258-K and other filingsReport will be filed late
23 Dec 20248-K and other filingsDirector or officer change
23 Dec 20248-K and other filingsDelisting notice or listing transfer
10 Oct 20248-K and other filingsDirector or officer change
10 Oct 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Jul 20248-K and other filingsDelisting notice or listing transfer
Insider net buying (open market)
Month from 1 Oct 2025: $3.3M published
Revenue per quarter
Quarter ended 31 Dec 2024: $663K; public on 15 Feb 2025
Quarter ended 31 Mar 2025: $15.0M; public on 21 May 2025
Institutional holders (13F filers)
31 Dec 2024 report: 8; public on 14 Feb 2025
31 Mar 2025 report: 7; public on 15 May 2025
30 Jun 2025 report: 8; public on 14 Aug 2025
30 Sep 2025 report: 15; public on 14 Nov 2025
31 Dec 2025 report: 20; public on 17 Feb 2026
31 Mar 2026 report: 18; public on 15 May 2026
30 Jun 2026 report: 22; public on 14 Aug 2026
30 Sep 2026 report: 18; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is revenue, quarter at $15.0M (31 Mar 2025), 23× its normal quarter.
  • Insider net buying (open market): Insiders bought a net $0 in the last 12 months (the 12 months before: $3.3M).
  • Revenue per quarter: Revenue $15.0M in the latest quarter.
  • Institutional holders (13F filers): 18 13F filers reported holding it in the latest 13F quarter, +20% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

18 institutions reported shares at the end of Q3 2026, 33% of the shares outstanding; 4 opened a position, 8 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Lynx1 Capital Management LP875K16.2%$3.1MNo change
AdvisorShares Investments LLC313K5.78%$1.1M+60K+24%
Vanguard Capital Management LLC173K3.21%$618KNo change
Shay Capital LLC130K2.40%$463K-26K-17%
Geode Capital Management, LLC51K0.94%$180K+1,120+2.3%
Ikarian Capital, LLC47K0.88%$169KNo change
Citadel Advisors LLC44K0.81%$157K-29K-39%
Vanguard Fiduciary Trust Co34K0.62%$120KNo change
ADAR1 Capital Management, LLC30K0.55%$107KNo change
Jane Street Group, LLC18K0.34%$65K+3,268+22%

Company events

All 16 company events

In 12 months: 3 major agreements, 1 delisting notice, 1 agreement ended. Results releases and routine reports are left out.

FiledWhat happenedSource
23 Oct 2026Signed a major agreementSame filing: changed shareholder rights8-K
23 Jul 2026Signed a major agreementSame filing: change of control8-K
7 Jan 2026Signed a major agreement; A major agreement ended8-K
18 Dec 2025Delisting notice or listing transfer8-K
27 Oct 2025Signed a major agreementSame filing: changed shareholder rights, changed its bylaws or fiscal year8-K
16 Sep 2025Delisting notice or listing transfer8-K
18 Jul 2025Delisting notice or listing transfer8-K
15 May 2025Quarterly report will be filed lateNT 10-Q

The 5 newest of 73 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 7 Jan 2026Filings record

    A major agreement ended

  2. 18 Dec 2025Filings record

    Delisting notice or listing transfer

  3. 24 Oct 2025Insiders record

    Lynx1 Capital Management LP (ten percent owner) and 1 other(s) bought 639,110 shares of NEUP ($3.3M) (dated 23 Oct 2025)

  4. 16 Sep 2025Filings record

    Delisting notice or listing transfer

  5. 18 Jul 2025Filings record

    Delisting notice or listing transfer

  6. 15 May 2025Filings record

    Report will be filed late

  7. 23 Dec 2024Filings record

    Director or officer change

  8. 23 Dec 2024Filings record

    Delisting notice or listing transfer

  9. 10 Oct 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  10. 10 Oct 2024Filings record

    Director or officer change

  11. 16 Jul 2024Filings record

    Delisting notice or listing transfer

Not listed: 27 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001191070
Ticker
NEUP
Domain
neuphoriatx.com
Hq location
MA|BURLINGTON|01803 (1 unverified)
Name
BIONOMICS LIMITED/FI, Neuphoria Therapeutics Inc.
  • SEC Form 13F institutional holdings72 data points31 Dec 2024 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)36 records14 Oct 2022 to 16 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)155 data points30 Jun 2022 to 13 Nov 2026
  • SEC Form 4 insider transactions1 record, 4 data points23 Oct 2025 to 23 Oct 2025
  • FINRA short interest (twice monthly)135 data points31 Dec 2024 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)958 data points24 Dec 2024 to 20 Nov 2026